scholarly journals Short- and long-term effects of exercise on neck muscle function in cervical radiculopathy: A randomized clinical trial

2016 ◽  
Vol 25 ◽  
pp. e72
Author(s):  
M. Halvorsen ◽  
D. Falla ◽  
L. Gizzi ◽  
K. Harms-Ringdahl ◽  
A. Peolsson ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Muscle Function ◽  
Cervical Radiculopathy ◽  
Neck Muscle ◽  
Long Term Effects ◽  
Short And Long Term

Short- and long-term effects of mud-bath treatment on hand osteoarthritis: a randomized clinical trial

2013 ◽  
Vol 58 (1) ◽  
pp. 79-86 ◽  
Author(s):  
Antonella Fioravanti ◽  
Sara Tenti ◽  
Chiara Giannitti ◽  
Nicola Angelo Fortunati ◽  
Mauro Galeazzi
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Hand Osteoarthritis ◽  
Long Term Effects ◽  
Short And Long Term

scholarly journals LONG-TERM EFFECTS OF EPIRUBICIN ON INCIDENCE OF HEART FAILURE IN WOMEN WITH BREAST CANCER: DATA FROM A RANDOMIZED CLINICAL TRIAL

2016 ◽  
Vol 67 (13) ◽  
pp. 1513
Author(s):  
Ann Bøcher Secher Banke ◽  
Emil Fosbol ◽  
Jacob Møller ◽  
Gunnar Gislason ◽  
Mads Andersen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Heart Failure ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Breast Cancer Data ◽  
Long Term Effects ◽  
Cancer Data

Comparing Short- and Long-Term Group Therapy: Seven-Year Follow-Up of a Randomized Clinical Trial

2015 ◽  
Vol 84 (5) ◽  
pp. 320-321 ◽  
Author(s):  
Steinar Lorentzen ◽  
Anette Fjeldstad ◽  
Torleif Ruud ◽  
Per A. Høglend
Keyword(s):  
Clinical Trial ◽  
Group Therapy ◽  
Randomized Clinical Trial ◽  
Short And Long Term

Poster 128: Long-term Effects of Physiotherapy-based Rehabilitation After Disk Herniation Operation: 12 Years' Follow-up of a Randomized Clinical Trial

PM&R ◽  
2010 ◽  
Vol 2 ◽  
pp. S61-S61
Author(s):  
Gerold Ebenbichler ◽  
Gabriele Amtmann ◽  
Silke Inschlag ◽  
Klaus Novak ◽  
Verena Pflüger ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Disk Herniation ◽  
Long Term Effects

scholarly journals Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial

2013 ◽  
Vol 28 (11) ◽  
pp. 2823-2833 ◽  
Author(s):  
Alireza Esteghamati ◽  
Sina Noshad ◽  
Sorour Jarrah ◽  
Mostafa Mousavizadeh ◽  
Seyed Hamid Khoee ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Diabetic Nephropathy ◽  
Angiotensin Ii ◽  
Randomized Clinical Trial ◽  
Ace Inhibitors ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Long Term Effects ◽  
Mineralocorticoid Receptor Antagonist

Abstract Background Addition of spironolactone (SPR) to angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) might provide antiproteinuric effects beyond what is gained by either medication alone. This study was designed to assess the long-term efficacy of SPR/ARB combination in comparison with the standard ACE/ARB regimen in diabetic nephropathy. Methods In an open-label, parallel-group, single-center, randomized clinical trial (NCT01667614), 136 patients with diabetes and proteinuria, already treated with enalapril and losartan, were included. In 74 patients, ACE inhibitors were discontinued. After a wash-out period of 2 weeks, 25 mg SPR daily was initiated. The remainder of the patients (n = 62) received ACE inhibitors and ARBs as before. Patients were followed every 3 months for 18 months. During each visit, systolic and diastolic blood pressure (BP), urinary albumin excretion (UAE), serum creatinine, estimated glomerular filtration rate (eGFR) and serum potassium concentrations were determined. Results After 18 months, three patients in the SPR/ARB group developed asymptomatic hyperkalemia. SPR/ARB significantly reduced both systolic and diastolic BP (P < 0.001 and 0.001, respectively). SPR/ARB decreased UAE by 46, 72 and 59% after 3, 12 and 18 months, respectively. Compared with the continuation regimen, SPR/ARB was superior in UAE reduction (P = 0.017 after 18 months), independent of BP change. In both groups, eGFR declined significantly over the trial course and the decline rate did not differ significantly between the two groups. Conclusions Addition of SPR to ARB provides added benefits with respect to BP control and proteinuria diminution. These antiproteinuric effects are not accompanied by prevention of eGFR loss compared with conventional therapy with ACE/ARB.

Sign in / Sign up

Export Citation Format

Share Document